# Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

> **NCT00575016** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 74 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **BIOLOGICAL:** Normal saline (Placebo); botulinum toxin Type A (200U)
- **BIOLOGICAL:** botulinum toxin Type A (50U); botulinum toxin Type A (200U)
- **BIOLOGICAL:** botulinum toxin Type A (100U); botulinum toxin Type A (200U)
- **BIOLOGICAL:** botulinum toxin Type A (200U)

## Key facts

- **NCT ID:** NCT00575016
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2010-02
- **Final completion:** 2010-07
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** The study was terminated early due to enrollment challenges.
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575016, "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00575016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*